{
  "UVB": {
    "BCVA": "best corrected visual acuity",
    "ICBD": "International Criteria Behçet Disease",
    "OCT": "Optical Coherence Tomography"
  },
  "OPTISAGE": {
    "AML": "acute myeloid leukemia",
    "RIC": "reduced intensity conditioning",
    "EFS": "event free survival",
    "GVL": "graft versus leukemia",
    "ATG": "Anti thymocyte globulins",
    "MUD": "matched unrelated donor",
    "GRFS": "GVHD relapse free survival"
  },
  "FOCUS": {
    "NIU": "non infectiuous uveitis",
    "BCVA": "best corrected visual acuity",
    "OCT": "optical coherence tomographic",
    "GFR": "Glomerular filtration rates",
    "NYHA": "New York Heart Association"
  },
  "KAPVEC": {
    "KS": "Kaposi sarcoma",
    "MCC": "Merkel cell carcinoma",
    "BORR": "best overall response rate"
  },
  "ERYTHROSIM": {
    "PRCA": "pure red cell aplasia"
  },
  "FIBRAPLO": {
    "OS": "overall survival",
    "DFS": "disease free survival"
  },
  "TEOREM": {
    "CD": "Crohn disease",
    "AIEC": "adherent invasive E coli"
  },
  "HAPLORESCUE": {
    "DSA": "donor specific antibody"
  },
  "GREEN": {
    "ADA": "Anti-glenzocimab Drug Antibodies",
    "ANSM": "Agence Nationale de Sécurité des Médicaments et des Produits de santé",
    "CPP": "Comité de Protection des Personnes",
    "EVT": "Endovascular therapy",
    "IVT": "Intravenous thrombolysis",
    "MCA": "Middle Cerebral Artery",
    "MT": "mechanical thrombectomy",
    "MRI": "magnetic resonance imaging",
    "MRA": "magnetic resonance angiography",
    "AIS": "acute ischemic stroke",
    "LVO": "large vessel occlusion",
    "ICA": "internal carotid artery",
    "CTA": "CT angiography",
    "CTP": "Perfusion CT-scan",
    "DAPT": "dual anti platelet therapy",
    "ICH": "IntraCranial Hemorrhages",
    "CCTAE": "common toxicity criteria",
    "AE": "adverse effect",
    "SAE": "serious adverse event",
    "SUSAR": "Suspected Unexpected Serious Adverse Reaction",
    "BRE": "Bleeding-Related Event",
    "TEAE": "Treatment Emergent Adverse Event",
    "SAEs": "serious adverse events",
    "SUSARs": "suspected unexpected serious adverse reactions",
    "BREs": "bleeding related events"
  },
  "SONIMEL": {
    "BBB": "Blood Brain Barrier",
    "US": "UltraSound",
    "MSD": "most successful dose",
    "ECOG": "Eastern Cooperative Oncology Group",
    "PS": "performance status"
  },
  "ITAC": {
    "BD": "Behçet disease"
  },
  "PCL-2": {
    "ANSM": "Agence Nationale de Sécurité des Médicaments et des Produits de santé",
    "ALT": "Alanine aminotransferase",
    "ANC": "absolute neutrophil count",
    "AST": "and aspartate aminotransferase",
    "ASCT": "autologous stem cell transplantation",
    "CBC": "Complete Blood Count",
    "CCTAE": "common toxicity criteria",
    "CPP": "Comité de Protection des Personnes",
    "CR": "Complete Response",
    "DOR": "Duration of response",
    "ECOG": "Eastern Cooperative Oncology Group",
    "EOT": "End of Treatment",
    "GI": "Gastro intestinal",
    "IMWG": "International Myeloma Working Group",
    "ISS": "International Staging System",
    "VRD": "Bortezomib-Lenalidomide-Dexamethasone",
    "MHSC": "Mobilization and harvesting stem cells",
    "MM": "multiple myeloma",
    "MRD": "minimal residual disease",
    "NCI": "National Cancer Institute",
    "NGS": "Next-Generation Sequencing",
    "ORR": "Overall response rate",
    "OS": "overall survival",
    "PBSC": "Peripheral Blood Hematopoietic Stem Cells",
    "PCL": "primitive plasma cell leukemia",
    "PFS": "progression-free survival",
    "SAE": "Serious Adverse Event",
    "SC": "Subcutaneous",
    "SPM": "Second primary malignancy",
    "TEAE": "Treatment Emergent Adverse Event",
    "TTP": "Time to progression",
    "ULN": "upper limit normal",
    "VGPR": "Very Good Partial Response",
    "pPCL": "Primary plasma cell leukemia",
    "PCR": "polymerase chain reaction",
    "HBV": "hepatitis B virus",
    "GCP": "good clinical practice",
    "ICH": "International Conference Harmonization"
  },
  "ICE": {
    "MC": "mixed cryoglobulinaemia",
    "MGUS": "monoclonal gammapathy unknown significance",
    "BVAS": "Birmingham Vasculitis Activity Score"
  },
  "METIMGAST": {
    "ORR": "overall response rate",
    "HIV": "Human Immunodeficiency Virus",
    "CNS": "central nervous system"
  },
  "INTORETAK": {
    "TA": "Takayasu arteritis",
    "CS": "corticosteroids",
    "ACR": "American College Rheumatology",
    "HIV": "human immunodeficiency virus"
  },
  "PARADISE": {
    "LIST": "OF ABBREVIATIONS AND RELEVANT DEFINITIONS",
    "AE": "Adverse Event",
    "AR": "Adverse Reaction",
    "ASR": "Annual Safety Report",
    "CA": "Competent Authority",
    "CBC": "Complete Blood Count",
    "CD": "Crohn’s Disease",
    "CDED": "Crohn Disease Exclusion Diet",
    "CDAI": "Crohn’s Disease Activity Index",
    "CDEIS": "Crohn’s Disease Endoscopic Index of Severity",
    "CRA": "Clinical Research Associate",
    "CRP": "C-reactive protein",
    "CV": "Curriculum Vitae",
    "DSMB": "Data Safety Monitoring Board",
    "EEN": "Exclusive Enteral Nutrition",
    "FCP": "Faecal Calprotectin",
    "GCP": "Good Clinical Practice",
    "HBI": "Harvey-Bradshaw Index",
    "IBD": "Inflammatory Bowel Disease",
    "IBDQ": "Inflammatory Bowel Disease Questionnaire",
    "ICF": "Informed Consent Form",
    "ITT": "Intent-to-treat principle",
    "PCC": "PillCam Crohn Capsule",
    "PEN": "Partial Enteral Nutrition",
    "PIL": "Patient Information Letter",
    "SAP": "Statistical Analysis Plan",
    "SES-CD": "Simple Endoscopic Score for Crohn’s Disease",
    "SF16": "Short Form 16",
    "SUSAR": "Suspected Unexpected Serious Adverse Reaction",
    "WPAI": "Work Productivity Index"
  },
  "FIRST": {
    "OS": "Overall Survival",
    "DFS": "disease free survival",
    "NRM": "Non relapse mortality",
    "BMI": "Body Mass Index",
    "PBSC": "peripheral blood stem cell",
    "CR": "complete remission"
  },
  "APARR": {
    "HSCT": "Hematopoietic Stem Cell Transplantation",
    "AA": "aplastic anemia",
    "EPAG": "eltrombopag",
    "PNH": "paroxysmal nocturnal hemoglobinuria",
    "AML": "acute myeloid leukemia",
    "GvHD": "graft versus host disease"
  },
  "RECORDS": {
    "LIST": "OF ABBREVIATIONS",
    "ADR": "Adverse Drug Reaction",
    "AE": "Adverse Event",
    "AGEPS": "Agence générale des équipements et produits de santé-APHP",
    "ANSM": "Agence nationale de sécurité du médicament et des produits de santé",
    "APHP": "Paris Public Hospital Assistance",
    "CMU": "Couverture Maladie Universelle",
    "CRF": "Case Report Form",
    "CRP": "C-reactive protein",
    "CTA": "Clinical Trial Application",
    "DSMC": "Data Safety Monitoring Committee",
    "DRCI": "Delegation of Clinical Research and Innovation",
    "EDC": "Electronic Data Capture",
    "ELISA": "Enzyme Linked ImmunoSorbent Assay",
    "ICU": "intensive care unit",
    "IPDMA": "Individual Patient Data Meta-Analysis",
    "IRB": "Institutional Review Board",
    "MDW": "Monocyte distribution width",
    "DUSP-1": "Dual-Specificity Phosphatase 1",
    "RCT": "Randomized Controlled Trial",
    "REB": "Research Ethics Board",
    "SADR": "Serious Adverse Drug Reaction",
    "SAE": "Serious Adverse Event",
    "SOFA": "score Sequential Organ Failure Assessment score",
    "SUADR": "Serious Unexpected Adverse Drug Reaction",
    "SUSAR": "Suspected Unexpected Serious Adverse Reaction",
    "URC": "HUPIFO Paris Ile de France Ouest Clinical Research Unit",
    "WHO": "World Health Organization",
    "CS": "corticosteroids"
  },
  "EFRAIM-II": {
    "ARF": "Acute respiratory failure",
    "DNI": "Do Not Intubate",
    "DNR": "Do Not Resuscitate"
  },
  "SALMA": {
    "AML": "Acute Myeloid Leukemias",
    "SOC": "standard of care",
    "HSCT": "hematopoietic stem cell transplantation",
    "IDA": "idarubicin",
    "CR": "complete remission",
    "ED": "early date",
    "EFS": "event free survival",
    "DLTs": "dose limiting toxicities",
    "MTD": "maximal tolerated dose",
    "SSZ": "Sulfasalazine",
    "DLT": "dose limiting toxicity",
    "PK": "pharmacokinetics",
    "PD": "pharmacodynamics",
    "EOI": "end of induction",
    "AE": "Adverse events",
    "TEAE": "treatment emergent adverse events",
    "SAEs": "serious adverse events",
    "DSMB": "data safety monitoring board",
    "ULN": "upper limit normal",
    "GFR": "glomerular filtration rate",
    "DL": "dose levels",
    "MRD": "minimal residual disease",
    "CRM": "continual reassessment method"
  },
  "KAPKEY": {
    "KS": "Kaposi sarcoma",
    "BORR": "Best Overall Response Rate",
    "CTCAE": "Common Terminology Criteria Adverse Events",
    "ANC": "Absolute neutrophil count"
  },
  "HAPLO-EMPTY": {
    "SAA": "severe aplastic anemia",
    "MUD": "matched unrelated donor",
    "ELT": "eltrombopag",
    "PNH": "paroxysmal nocturnal hemoglobinuria",
    "AML": "acute myeloid leukemia",
    "HSCT": "Hematopoietic stem cell transplantation",
    "GvHD": "Graft versus Host Disease",
    "OS": "overall survival"
  },
  "MAC-HAPLO-MUD": {
    "SCT": "stem cell transplantation",
    "MUD": "matched unrelated donors",
    "PBSC": "Peripheral blood stem cell",
    "HR": "Hazard ratio"
  },
  "MSC-SLE": {
    "SLE": "Systemic Lupus Erythematosus",
    "AD": "auto Disease",
    "MSC": "Mesenchymal Stem cells",
    "WHO": "World Health Organization",
    "MCR": "Major Clinical Response"
  },
  "RUBI": {
    "LIST": "OF ABBREVIATIONS",
    "ADA": "Anti-drug antibodies",
    "ADCC": "Antibody dependent cell-mediated cytotoxicity",
    "AE": "Adverse event",
    "ALT": "Alanine amino transferase",
    "AST": "Aspartate amino transferase",
    "ATC": "Anatomical-Therapeutic-Chemical classification",
    "AUC": "Area under the curve",
    "AZA": "Azathioprine",
    "BCVA": "best corrected visual acuity",
    "BRB": "Blood-retinal barrier",
    "BUN": "Blood urea nitrogen",
    "CBC": "Complete blood count",
    "CHO": "Chinese hamster ovary",
    "CINCA": "Chronic Infantile Neurological Cutaneous Articular",
    "CRF": "Case Report Form",
    "CSA": "Cyclosporine A",
    "CTCAE": "Common Terminology Criteria for Adverse Events",
    "EAU": "Experimental autoimmune uveitis/uveoretinitis",
    "NIU": "Non infectious Uveitis",
    "OCT": "ocular coherence tomography",
    "CME": "cystoid macular edema",
    "MAMS": "Multi Arm Multi Stage"
  },
  "CAALLF01": {
    "ALL": "acute lymphoblastic leukemia",
    "API": "Active Pharmaceutical Ingredient",
    "CMO": "Contract Manufacturing Organization",
    "CNS": "Central Nervous System",
    "CR": "complete remission",
    "DFS": "disease-free survival",
    "DNR": "daunorubicine",
    "DEX": "dexamethasone",
    "EFS": "event-free survival",
    "EIG": "événement indésirable grave (voir SAE)",
    "GMP": "Good Manufacturing Practices",
    "HD-MTX": "high-dose methotrexate",
    "HR": "High Risk",
    "HSCT": "Hematopietic Stem Cell Transplantation",
    "IM": "intramuscular",
    "IMP": "Investigational Medicinal Product",
    "IT": "intrathecal injection",
    "IV": "intravenous infusion",
    "MR": "Medium Risk",
    "MRD": "Minimal Residual Disease",
    "MTX": "methotrexate",
    "NCI": "National Cancer Institute",
    "NCI-CTCAE": "National Cancer Institute Common Terminology Criteria for Adverse Events",
    "OS": "overall survival",
    "PEG": "pegaspargase",
    "PNN": "neutrophils",
    "PRED": "prednisone",
    "SAE": "severe adverse event",
    "SR": "Standard Risk",
    "TP": "Time Point",
    "TLP": "traumatic lumbar puncture",
    "VCR": "vincristine",
    "VHR": "Very High Risk",
    "WBC": "White Blood Cell Count",
    "ASNase": "asparaginase",
    "DI": "delayed intensifications",
    "GPR": "Good prednisone response",
    "PPR": "Poor Prednisone response"
  },
  "CAMOVID": {
    "ACE2": "Angiotensin Converting Enzyme 2",
    "AGEPS": "Agence générale des équipements et produits de santé",
    "AE": "adverse event",
    "ANSM": "Agence nationale de sécurité du medicament et des produits de santé",
    "APHP": "Assistance Publique Hôpitaux de Paris",
    "ALT": "Alanine aminotransferase",
    "ANC": "Absolute neutrophil count",
    "AST": "Aspartate aminotransferase",
    "BMI": "Body mass index",
    "BUN": "Blood urea nitrogen",
    "CNIL": "Commission nationale informatique et libertés",
    "COPD": "chronic obstructive pulmonary disease",
    "CPK": "Creatinine phosphokinase",
    "CPP": "comité de protection des personnes",
    "CRA": "Clinical Research Associates",
    "CRB": "Centre de Ressources Biologiques",
    "CRP": "C Reactive protein",
    "CRPV": "Centre Régional de Pharmacovigilance",
    "CTCAE": "Common Terminology Criteria for Adverse Events",
    "DRCI": "Délégation à la Recherche Clinique et à l’Innovation",
    "DSMB": "Data safety monitoring board",
    "DSUR": "Development Safety Update Report",
    "ECMO": "extra corporeal membrane oxygenation",
    "EMA": "European Medicine Agency",
    "ER": "emergency room",
    "GCP": "Good Clinical Practices",
    "GP": "general practitioner",
    "HCSP": "Haut Conseil à la Santé Publique",
    "ICU": "intensive care unit",
    "ITT": "intent to treat",
    "IEAC": "independent endpoint adjudication comittee",
    "NIV": "non invasive ventilation",
    "PHRC": "programme hospitalier de recherche clinique",
    "PI": "principal investigator",
    "RTPCR": "reverse transcription polymerase chain reaction",
    "RRT": "renal replacement therapy",
    "SAE": "serious adverse event",
    "SBIM": "Service de Biostatistique et Information Médicale",
    "TMPRSS2": "cellular serine protease",
    "WHO": "World health organization",
    "AEs": "Adverse events",
    "GPs": "general practitioners",
    "GHSIF": "Groupe Hospitalier Sud Ile France"
  },
  "MSC-AT-SSC": {
    "AD": "autoimmune disease",
    "AE": "Adverse Events",
    "AHSCT": "autologous hematopoietic stem cell transplantation",
    "BMI": "Body Mass Index",
    "CTC-AE": "NCI Common Terminology Criteria for Adverse Events",
    "CRISS": "ACR Provisional Composite Response Index for Clinical Trials in Early Diffuse",
    "DLCO": "diffusing capacity of lung for carbon monoxide",
    "EQ-5D-5L": "EuroQol 5-Dimension 5-Level",
    "FVC": "Forced Vital Capacity",
    "GMP": "Good Manufacturing Practices",
    "GRCS": "Global Rank Composite Score",
    "IV": "intravenous",
    "MMF": "Mycophenolate mofetil",
    "MSC": "Mesenchymal stromal cells",
    "QALY": "Quality-Adjusted Life Year",
    "PFS": "Progression free survival",
    "SAE": "Severe Adverse Events",
    "SAR": "Serious Adverse Reactions",
    "SHAQ": "Scleroderma-Health Assessment Questionnaire",
    "SF-36": "The Short Form (36) Health Survey",
    "TRSAE": "treatment related Severe Adverse Events",
    "CTCAE": "Common Terminology Criteria Adverse Events",
    "DSMB": "Data Safety Monitoring Board"
  },
  "TRIBECA": {
    "WCBP": "Women Child Bearing Potential"
  },
  "UPFRONT-MUD": {
    "AA": "aplastic anemia",
    "FFS": "failure free survival",
    "MUD": "matched unrelated donor",
    "HSCT": "hematopoietic stem cell transplantation",
    "GvHD": "Graft versus Host Disease"
  },
  "JAKAHDI": {
    "HS": "Hemophagocytic syndrome"
  },
  "SHORTCUT": {
    "KTR": "kidney transplant recipients",
    "UTI": "urinary tract infection",
    "MDR": "Multidrug"
  },
  "DREPA-RIC": {
    "SCD": "sickle cell disease",
    "HSCT": "hematopoietic stem cell transplantation",
    "MRD": "matched related donor",
    "GVHD": "graft versus host disease",
    "TBI": "total body irradiation",
    "CT": "computed tomography",
    "TP": "transfusion program",
    "GFR": "glomerular fraction rate"
  },
  "GRAALL-2014": {
    "HSCT": "Haematopoietic Stem Cell Transplantation",
    "ALAT": "Alanine-Aminotransferase IT: Intra-thecal",
    "ALL": "Acute Lymphoblastic Leukemia IUD: Intrauterine Device",
    "ANSM": "“Agence Nationale de sécurité du IV: Intravenous",
    "ASAT": "Aspartate Amino Transferase LR: Low Risk",
    "AT": "Anti Thrombin LWH: Low Weight Heparin",
    "ATG": "Anti ThymoGlobulin MAC: Myelo Ablative Conditioning",
    "BID": "Twice a day MMolR: Major Molecular Response",
    "BM": "Bone Marrow MRD: Minimal Residual Disease",
    "BMI": "Body Mass Index MRI: Magnetic Resonance Imaging",
    "CIR": "cumulative incidence relapse",
    "CIV": "ContinuousIntravenous NRM: Non Relapse related Mortality",
    "CML": "ChronicMyelogenous Leukemia NYHA: “New York Heart Association”",
    "CNS": "central nervous system",
    "CPM": "Cyclophosphamide PB: Peripheral BloodPHRC: “Programme Hospitalier",
    "CPP": "“Comité de Protection des Personnes” de Recherche Clinique”",
    "CR": "Complete Remission ANC: Polymorphonuclears",
    "CRA": "Clinical Research Assistant PO: Per Os",
    "CRF": "Case Report Form PS: Performans Status (= ECOG)",
    "CSF": "Cerebro Spinal Fluid RBC: Red Blood Cells",
    "DFS": "disease free survival",
    "DIVC": "Disseminated Intravascular Coagulation RTC: Reduced Toxicity Conditioning",
    "DMA": "Drug Marketing Authorization SAE: Serious Adverse Event",
    "DNR": "Daunorubicin SC: SubCutaneous",
    "DVI": "Dexamethasone, Vincristine, ITK SGOT: Serum Glutamic OxaloaceticTransferase",
    "ECG": "Electrocardiogram SGPT: Serum GlutamopyruvateTransferase",
    "ECOG": "Eastern Cooperative Oncology Group (= PS) SIV: Slow Intravenous",
    "FFD": "Form of Functions Delegation SPC: Summary of Product Characteristics",
    "FFP": "Fresh Frozen Plasma SR: Standard Risk",
    "FGM": "France Greffe de Moelle TBI: Total Body Irradiation",
    "FR": "Shortening Fraction TD: Total Dose",
    "GCP": "Good Clinical Practice TDM: Tomodensitometry",
    "G-CSF": "Granulocyte colony-stimulating factor TKI: Tyrosine Kinase Inhibitor",
    "GNB": "Gram Negative Bacteria TLP: Traumatic Lumbar Puncture",
    "GPB": "Gram Positive Bacteria TUA: Temporary Usage Authorization",
    "GVH": "Graft versus Host ULN: Upper Limit of Normal",
    "HCR": "Hematologic Complete Remission VCR: Vincristine",
    "HD": "High Dose VDS: Vindesine",
    "HLA": "Human Leukocyte Antigen VEF: Ventricular Ejection Fraction",
    "HR": "high risk",
    "HSC": "Hematopoietic Stem Cells VP-16: Etoposide",
    "WBC": "White Blood Cells",
    "GRAALL-2014": "–Summary 4/178",
    "SR": "Standard risk",
    "NRM": "non relapse mortality",
    "OS": "overall survival",
    "SAEs": "Serious adverse events"
  },
  "MARVEL": {
    "DME": "drug metabolizing enzymes",
    "MAR": "missing at random",
    "ODV": "ODemethylV"
  },
  "PIPAC": {
    "QoL": "quality of life",
    "CI": "Confidence Intervals"
  }
}